Introduction {#Sec1}
============

*Candida* species are among the most common causative agents of nosocomial bloodstream infections \[[@CR1]\]. In critically ill intensive care unit (ICU) patients, the incidence rate of *Candida* bloodstream infection (candidemia) is estimated at between 2.1 and 6.9 cases per 1000 ICU admissions \[[@CR2]--[@CR4]\], with a high crude mortality rate of 43--61% \[[@CR2]--[@CR5]\].

To date, many studies have investigated factors associated with mortality among candidemia patients across several clinical settings. However, most of the studies included non-ICU patients and therefore, little is known about prognostic factors in ICU patients with candidemia. Specifically, a limited number of studies have investigated the impact of early appropriate antifungal therapy and/or early removal of central venous catheter (CVC) on mortality, with inconsistent results \[[@CR2]--[@CR6]\].

Consequently, in this study, we investigated the relationship between clinically relevant factors, including early treatment (appropriate antifungal therapy and/or CVC removal) and mortality in ICU patients with candidemia.

Methods {#Sec2}
=======

Study design and patient selection {#Sec3}
----------------------------------

We conducted a bicentric, retrospective observational study in two university hospitals in Japan between January 2007 and December 2016. Participating hospitals included the Hiroshima University Hospital (746 beds) and the University Hospital, Kyoto Prefectural University of Medicine (1065 beds). We used the microbiological database of each participating hospital to identify positive blood cultures for *Candida* species. We included adult ICU patients with candidemia who met the following inclusion criteria: (1) were ≥ 18 years old; (2) were admitted in the ICU at the time of onset; and (3) had a CVC in situ at the time of onset.

All data were anonymized, and the requirement for informed consent was waived due to the retrospective study design. This study was approved by the institutional review board of Hiroshima University (approval number: E-746) and Kyoto Prefectural University of Medicine (approval number: ERB-C-1162).

Patient variables and outcomes {#Sec4}
------------------------------

The following information was collected from each patient's medical record for covariates: age at onset; sex; time from hospital admission to onset; Acute Physiology and Chronic Health Evaluation (APACHE) II score ≤ 24 h following onset; comorbidities and prior treatment exposure (solid organ malignancy ≤ 1 year before onset, hematological malignancy ≤ 1 year before onset, previous solid organ transplantation, previous hematopoietic stem cell transplantation, liver disease, diabetes mellitus, autoimmune disease, neutropenia, abdominal surgery ≤ 3 months before onset, invasive mechanical ventilation at the time of onset, renal replacement therapy ≤ 30 days before onset, total parenteral nutrition \[TPN\] at the time of onset, antibiotic therapy \[for ≥ 3 days\] ≤ 30 days before onset, antifungal therapy \[for ≥ 3 days\] ≤ 30 days before onset, immunosuppressive therapy ≤ 30 days before onset); shock ≤ 24 h following onset; concurrent bacteremia at onset; breakthrough candidemia; causative *Candida* species; source of candidemia; treatment ≤ 24 h following onset (appropriate antifungal therapy alone, CVC removal alone, or a combination of them \[combined intervention\]); and treatment ≤ 48 h following onset.

The primary outcome of this study was 30-day crude mortality.

Definitions {#Sec5}
-----------

Candidemia was defined as the isolation of *Candida* species from at least one blood culture. Candidemia onset was defined as the time when the first positive blood culture for *Candida* species was drawn from the patient. Neutropenia was defined as an absolute neutrophil count \< 500 cells/mm^3^. Immunosuppressive therapy was defined as the administration of corticosteroids, chemotherapy drugs, or other immunosuppressive drugs. Shock was defined as the initiation or increment of inotropes/vasopressors ≤ 24 h following onset to maintain a mean arterial blood pressure of ≥ 65 mmHg. Breakthrough candidemia was defined as candidemia that occurred in patients receiving antifungal agents at the time of onset for ≥ 3 days. CVC-related candidemia was defined as the isolation of the same *Candida* species from blood culture and CVC tip culture. Appropriate antifungal therapy was defined as the administration of the correct dose of antifungal agent for a susceptible *Candida* species. Correct doses of antifungal agents were defined as follows: caspofungin, loading dose of 70 mg, then 50 mg daily; micafungin, 100--150 mg daily; liposomal amphotericin B, 2.5--5 mg/kg daily; fluconazole, loading dose of 800 mg (or 12 mg/kg), then 400 mg (or 6 mg/kg) daily; fosfluconazole, loading dose of 800 mg (or 12 mg/kg) daily for 2 days, then 400 mg (or 6 mg/kg) daily; and voriconazole, loading dose of 400 mg (or 6 mg/kg) twice daily for 2 doses, then 200--300 mg (or 3--4 mg/kg) twice daily \[[@CR7], [@CR8]\]. Antifungal susceptibility was determined using the guidelines in the Clinical and Laboratory Standard Institute document M27-S3 \[[@CR9]\].

Candidemia occurring \> 30 days following the preceding candidemia onset was considered as a new episode. We only included the first episode of candidemia during the study period in the analyses.

Microbiological procedures {#Sec6}
--------------------------

In both participating hospitals, *Candida* species were isolated using an automated blood culture system (BACT/ALERT 3D; bioMérieux, Tokyo, Japan) and identified using the VITEK 2 YST ID card (bioMérieux).

Statistical analysis {#Sec7}
--------------------

Qualitative variables were reported as frequencies and percentages. Quantitative variables were reported as means and standard deviations (SDs) when parametric, or as medians and interquartile ranges (IQRs) when nonparametric. Qualitative variables were analyzed using Fisher's exact test. Parametric data were analyzed using the *t* test, and nonparametric data were analyzed using the Mann-Whitney *U* test. We performed univariate and multivariate logistic regression analysis to identify factors associated with 30-day crude mortality. We entered variables significant by univariate logistic regression analysis at the *P* \< 0.10 level, as well as prespecified variables, into the multivariate logistic regression analysis. The following prespecified variables were selected on the basis of the results of previous studies and our clinical interest: APACHE II score ≤ 24 h following onset; treatment ≤ 24 h and ≤ 48 h following onset (appropriate antifungal therapy alone, CVC removal alone, or combined intervention). To assess the impact of these two different periods between the time of onset and intervention, we structured two multivariate logistic regression models. Furthermore, we conducted subgroup analyses for factors associated with mortality in patients with CVC-related and CVC-unrelated candidemia. All statistical tests were two-tailed and *P* values \< 0.05 were considered statistically significant.

Results {#Sec8}
=======

Patient characteristics at candidemia onset {#Sec9}
-------------------------------------------

We identified a total of 68 patients with a median age of 68.0 years (61.0--76.0) who met the inclusion criteria (Table [1](#Tab1){ref-type="table"}). Of these, 47 (69%) were males. The most common comorbidities were liver disease, diabetes mellitus, and autoimmune disease (for each, 14 \[21%\] patients). Fifty-six (82%) patients were receiving invasive mechanical ventilation at the time of onset. Within 30 days prior to onset, 65 (96%) patients had received antibiotics for ≥ 3 days. Table 1Patient characteristics at candidemia onsetVariablesTotal cohort\
(*n* = 68)30-day survivors\
(*n* = 31)30-day non-survivors\
(*n* = 37)*P* valueMale sex47 (69.1)22 (71.0)25 (67.6)0.798Age (years)68.0 (61.0--76.0)68.0 (58.0--76.0)68.0 (63.0--76.0)0.782Time from hospital admission to onset (days)24.5 (8.0--46.5)20.0 (6.0--42.0)26.0 (9.0--47.0)0.479APACHE II score (points)21.0 (18.0--26.0)19.0 (13.0--24.0)23.0 (19.0--27.0)0.003Comorbidities and prior treatment exposure Solid organ malignancy\*11 (16.2)6 (19.4)5 (13.5)0.531 Hematological malignancy\*2 (2.9)0 (0.0)2 (5.4)0.496 Solid organ transplantation4 (5.9)1 (3.2)3 (8.1)0.620 Hematopoietic stem cell transplantation1 (1.5)0 (0.0)1 (2.7)1.000 Liver disease14 (20.6)6 (19.4)8 (21.6)1.000 Diabetes mellitus14 (20.6)4 (12.9)10 (27.0)0.229 Autoimmune disease14 (20.6)7 (22.6)7 (18.9)0.769 Neutropenia (\< 500 cells/mm^3^)2 (2.9)0 (0.0)2 (5.4)0.496 Abdominal surgery\*\*18 (26.5)7 (22.6)11 (29.7)0.587 Invasive mechanical ventilation56 (82.4)23 (74.2)33 (89.2)0.124 Renal replacement therapy^†^23 (33.8)7 (22.6)16 (43.2)0.122 Total parenteral nutrition43 (63.2)18 (58.1)25 (67.6)0.458 Antibiotic therapy (for ≥ 3 days) ^†^65 (95.6)30 (96.8)35 (94.6)1.000 Antifungal therapy (for ≥ 3 days) ^†^6 (8.8)2 (6.5)4 (10.8)0.681 Immunosuppressive therapy^†^26 (38.2)9 (29.0)17 (46.0)0.211Shock42 (61.8)17 (54.8)25 (67.6)0.324Concurrent bacteremia22 (32.4)10 (32.3)12 (32.4)1.000Breakthrough candidemia6 (8.8)2 (6.5)4 (10.8)0.681Values are given as *n* (%) or median (interquartile range). *APACHE* acute physiology and chronic health evaluation.\*≤ 1 year before onset\*\*≤ 3 months before onset^†^≤ 30 days before onset

Causative Candida species and source of infection {#Sec10}
-------------------------------------------------

The most common causative *Candida* species was *Candida albicans* (40 \[59%\] patients), followed by *Candida glabrata* (17 \[25%\] patients) (Table [2](#Tab2){ref-type="table"}). Two causative *Candida* species were isolated simultaneously in six (9%) patients. With regard to the source of infection, CVC-related candidemia was the most frequent (30 \[44%\] patients), followed by intra-abdominal infection (10 \[15%\] patients). Table 2Causative *Candida* species and source of infectionVariablesTotal cohort (*n* = 68)30-day survivors (*n* = 31)30-day non-survivors (*n* = 37)*P* valueCausative *Candida* species\**Candida albicans*40 (58.8)19 (61.3)21 (56.8)0.806*Candida glabrata*17 (25.0)6 (19.4)11 (29.7)0.405*Candida parapsilosis*8 (11.8)3 (9.7)5 (13.5)0.719*Candida tropicalis*7 (10.3)3 (9.7)4 (10.8)1.000*Candida krusei*1 (1.5)1 (3.2)0 (0.0)0.456 Others1 (1.5)0 (0.0)1 (2.7)1.000Source of infection CVC-related30 (44.1)15 (48.4)15 (40.5)0.625 Intra-abdominal10 (14.7)4 (12.9)6 (16.2)0.745 Skin and soft tissue4 (5.9)3 (9.7)1 (2.7)0.324 Cardiovascular1 (1.5)0 (0.0)1 (2.7)1.000 Others or unknown23 (33.8)9 (29.0)14 (27.8)0.607Values are given as *n* (%). *CVC* central venous catheter\*Two causative *Candida* species were isolated simultaneously in 6 (8.8%) patients

Management of candidemia {#Sec11}
------------------------

For initial antifungal treatment (including inappropriate antifungal treatment), micafungin was most frequently used antifungal agent (in 41 \[60%\] patients), followed by liposomal amphotericin B (in 11 \[16%\] patients) (Table [3](#Tab3){ref-type="table"}). Within 48 h following onset, 9 (13%) patients received appropriate antifungal therapy alone, 18 (27%) patients had CVC removal alone, 16 (24%) patients received combined intervention, whereas 25 (37%) patients received either no treatment or inappropriate antifungal therapy alone. In addition, no patient received source control other than CVC removal ≤ 48 h following onset. Table 3Management of candidemiaVariablesTotal cohort (*n* = 68)30-day survivors (*n* = 31)30-day non-survivors (*n* = 37)*P* valueInitial antifungal agent\* Micafungin41 (60.3)19 (61.3)22 (59.5)1.000 Liposomal amphotericin B11 (16.2)6 (19.4)5 (13.5)0.531 Fluconazole7 (10.3)2 (6.5)5 (13.5)0.442 Voriconazole3 (4.4)2 (6.5)1 (2.7)0.588 None during candidemia7 (10.3)2 (6.5)5 (13.5)0.442Treatment ≤ 24 h following onset Appropriate antifungal therapy alone4 (5.9)3 (9.7)1 (2.7)0.324 CVC removal alone19 (27.9)9 (29.0)10 (27.0)1.000 Combined intervention5 (7.4)2 (6.5)3 (8.1)1.000Treatment ≤ 48 h following onset Appropriate antifungal therapy alone9 (13.2)3 (9.7)6 (16.2)0.494 CVC removal alone18 (26.5)8 (25.8)10 (27.0)1.000 Combined intervention16 (23.5)9 (29.0)7 (18.9)0.396Values are given as *n* (%). *CVC* central venous catheter\*Including antifungal agents used in inappropriate antifungal therapy

Outcome and factors associated with mortality {#Sec12}
---------------------------------------------

Thirty-day crude mortality was 54% (37 patients). In univariate analysis for mortality, the following two variables showed *P* values \< 0.10: APACHE II score ≤ 24 h following onset (1-point increments) (odds ratio \[OR\] 1.14, 95% confidence interval \[CI\] 1.04--1.25, *P* = 0.005); and renal replacement therapy ≤ 30 days before onset (OR 2.61, 95% CI 0.90--7.57, *P* = 0.077). In multivariate logistic regression analysis, only APACHE II score (1-point increments) was independently associated with higher 30-day crude mortality both in model 1 (OR 1.14, 95% CI 1.03--1.25, *P* = 0.007) and in model 2 (OR 1.14, 95% CI 1.04--1.26, *P*= 0.008) (Table [4](#Tab4){ref-type="table"}). Other variables, including treatment ≤ 24 h and ≤ 48 h following onset, did not significantly influence mortality. Table 4Multivariate logistic regression analysis of risk factors for 30-day mortalityVariablesModel 1Model 2OR (95% CI)*P* valueOR (95% CI)*P* valueAPACHE II score (1-point increments)1.14 (1.03--1.25)0.0071.14 (1.04--1.26)0.008Renal replacement therapy\*2.96 (0.91--9.61)0.0702.77 (0.87--8.80)0.085Treatment ≤ 24 h following onset None or inappropriate antifungal therapy aloneReference Appropriate antifungal therapy alone0.23 (0.02--3.12)0.267 CVC removal alone0.97 (0.29--3.29)0.961 Combined intervention1.66 (0.17--16.56)0.666Treatment ≤ 48 h following onset None or inappropriate antifungal therapy aloneReference Appropriate antifungal therapy alone1.06 (0.17--6.50)0.948 Source control alone1.15 (0.30--4.43)0.840 Combined therapy0.59 (0.14--2.39)0.456*APACHE* acute physiology and chronic health evaluation, *CI* confidence interval, *OR* odds ratio\*≤ 30 days before onset

Subgroup analysis in patients with CVC-related/-unrelated candidemia {#Sec13}
--------------------------------------------------------------------

Mortality rates did not differ significantly between patients with CVC-related candidemia (30 patients) and CVC-unrelated candidemia (38 patients) (50% vs 58%, *P* = 0.625). Univariate logistic regression analysis for mortality showed that the following host-related factors were significantly associated with poor 30-day survival: renal replacement therapy ≤ 30 days before onset (OR 12.25, 95% CI 1.27--118.36, *P* = 0.030) in CVC-related candidemia; APACHE II score ≤ 24 h following onset (1-point increments) (OR 1.17, 95% CI 1.03--1.33, *P* = 0.017); and TPN at onset (OR 4.37, 95% CI 1.07--17.79, *P* = 0.039) in CVC-unrelated candidemia. There was no significant association between early intervention (i.e., appropriate antifungal therapy and/or CVC removal) and mortality in the two subgroups. Due to the small sample size, we could not conduct multivariate logistic regression analysis among the subgroups.

Discussion {#Sec14}
==========

In this bicentric observational study, we investigated the characteristics and impact of host- and early treatment-related factors in ICU patients with candidemia. We found that APACHE II score ≤ 24 h following candidemia onset was the only parameter independently associated with death, and that none of the therapeutic interventions (including early empiric antifungal therapy and/or early CVC removal) had a significant impact on mortality. In subgroup analysis, we also found that the other two host-related factors (i.e., renal replacement therapy ≤ 30 days before onset in patients with CVC-related candidemia and TPN at onset in CVC-unrelated candidemia) but not early treatment-related factors were significantly associated with mortality in univariate logistic regression analyses, which supported the primary results.

According to the current published guidelines, prompt antifungal therapy and CVC removal are encouraged \[[@CR8], [@CR10]\]. There have been several positive results regarding the effect of early intervention on mortality in ICU patients with candidemia \[[@CR4], [@CR5], [@CR11]\]. One study in Spanish ICUs reported that combined intervention (i.e., appropriate antifungal therapy and CVC removal) ≤ 48 h following onset was significantly associated with lower early (≤ 7 days) crude mortality, but not with late (8--30 days) crude mortality \[[@CR5]\]. Another study in Indian ICUs demonstrated a significant association between early intervention and 30-day crude mortality \[[@CR4]\]. Surprisingly, the results from the present study are not in line with these findings. Differences in patients' age, background, proportion of CVC placement, or severity of illness among other studies and the present one might account for these discrepancies.

Conversely, and in line with findings from the present study, several studies reported no significant relationships between early intervention and mortality in ICU patients with candidemia \[[@CR2], [@CR12], [@CR13]\]. These studies consistently suggested that host-related factors (e.g. comorbidities, prior treatment exposure, or APACHE II score at diagnosis) had more impact on mortality than early intervention. Compared with other patients with bacteremia, patients with candidemia are often more severely ill, receive more organ support therapies (e.g., mechanical ventilation or vasopressors), and are associated with higher mortality rates \[[@CR14]--[@CR16]\]. Therefore, findings from the present and previous studies might be indicative that early interventions in ICU patients with candidemia have less impact on mortality compared to other ICU patients with bacteremia.

We should be aware that all aforementioned studies, including the present one, were observational in design, possibly containing various biases and unmeasured potential confounders. No meta-analysis or randomized trials have yet been conducted to investigate the effect of early intervention in ICU patients with candidemia \[[@CR17]\]. In the future, randomized studies targeting subgroups such as patients with septic shock due to candidemia could be considered, as several observational studies with positive results were derived from this population in the past \[[@CR18], [@CR19]\].

Our study has a strength in targeting patients with (1) microbiologically confirmed candidemia, (2) onset of candidemia during ICU stay, and (3) CVC in situ at the time of onset, in order to appropriately evaluate the effect of therapeutic intervention. On the other hand, this study had several limitations. Firstly, we could not assess candidemia-attributable mortality, which has been previously reported as 5--22% \[[@CR4], [@CR11], [@CR20]\]. However, there has been no accepted definition of attributable mortality and several studies even concluded that candidemia itself did not significantly increase mortality \[[@CR11], [@CR13]\]. Secondly, we could not perform subgroup analysis based on causative *Candida* species. According to a previous study, distribution of isolated *Candida* species among invasive candidiasis depends on various factors such as geography, underlying disease, and prior exposure to antibiotics \[[@CR21]\]. Further large-scale studies to assess whether clinical features and effects of therapeutic interventions depend on causative *Candida* species are warranted \[[@CR22]\]. Acknowledging these strengths and limitations, our study could demonstrate no significant clinical benefit of early intervention among ICU patients with candidemia and suggested the need to conduct a meta-analysis or randomized trial that would potentially impact future clinical practice guidelines.

Conclusions {#Sec15}
===========

Candidemia in ICU patients is still associated with high 30-day crude mortality rates. The only predictor of death was APACHE II score ≤ 24 h following candidemia onset. Early empiric antifungal therapy and/or early CVC removal conferred no significant clinical benefit on survival in this patient population.
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